David Berry, MD, PhD is a Principal at Flagship Ventures. He joined Flagship in 2005 while completing his M.D. from Harvard Medical School. David was previously awarded a Ph.D. through the MIT Biological Engineering Division, where he studied the biological effects of complex sugars with advisors Professor Ram Sasisekharan and Professor Robert Langer. David also did his undergraduate work at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain and cognitive sciences.
He was named as a member of the MIT Corporation - its Board of Trustees - in 2006. David's work has led to 11 peer-reviewed publications, over 20 patents and applications, as well as over twenty-five awards and honors including the prestigious Lemelson-MIT Student Prize in 2005 for invention and innovation. David was also named as the Innovator of the Year by Technology Review in its 2007 TR35 list of world's top 35 innovators under the age of 35.
At Flagship, David focuses on investing in and founding early stage life science and cleantech ventures and works closely with portfolio companies BG Medicine, T2 Biosystems, Epitome Biosystems and LS9.
I think you have to think in a way about what venture capitalists are actually doing. The common perception in some way is you put some money in, you're making an investment to basically that a company is going to grow. Really, since there's portfolio management what you're doing in every single i...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
